Watch the interview with Occlutech CEO Sabine Bois

Welcome Sabine! Welcome to the Anchor office in Stockholm. We've had the opportunity to work with you for a few years now. Would you like to give us some insights into Occlutech's journey, and how we have worked together?

- Thank you very much, and thank you for the invitation Peter. My name is Sabine, I am the CEO of Occlutech which is a medical device company in the cardiology field.

- When we met in 2021, we were preparing for an IPO here on the NASDAQ Stockholm Stock Exchange and there was a lot to do in terms of transformation. We had a very entrepreneurial background and had to get many processes in place.

- The ERP implementation of SAP was a major project, and we also introduced corporate governance in an IT QMS project.

- It has been a pleasure to have you as acting CIO, Peter. It's been a special experience because you really stepped into the role as part of the company. You took the position of the company and made decisions for the company with our perspective. That created a lasting value for us that we could then drive forward ourselves. Anchor's team contributed greatly to the success of our projects and brought them to fruition.

- Today we are ready for Main Market Listing and an IPO, and we are very happy and grateful for Anchor's support during these years.

We've had a great journey together with you, Sabine!
It's been fun and I hope we'll have the opportunity to work together again when new challenges appear on the horizon.
Thank you so much Sabine for being here today!

Sabine Bois

CEO Occlutech

Facts about Occlutech

Occlutech is a leading specialist provider of minimally invasive cardiac implants aimed at improving the quality of life for people with heart disease.

Since 2003, Occlutech has developed, produced and commercialized cardiac implants for congenital heart defects, stroke prevention and heart failure needs. The products are sold to hospitals and clinics in around 85 countries and are used by doctors in implantation procedures.

Headquartered in Switzerland, Occlutech employs approximately 320 people and has manufacturing and R&D facilities in Germany and Turkey, a global service, finance and distribution hub in Helsingborg, Sweden, and clinical operations in Minneapolis, USA.

Find out more at: https://www.occlutech.com